Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma

Dawn Swan; Mark Gurney; Janusz Krawczyk; Aideen E. Ryan; Michael O'Dwyer

doi:10.1097/HS9.0000000000000350

Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma

Dawn Swan
, Mark Gurney
, Janusz Krawczyk
, Aideen E. Ryan
, Michael O'Dwyer

Galway University Hospital
University of Galway

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

51 Citations (Scopus)

Abstract

The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.

Original language	English
Article number	e350
Journal	HemaSphere
Volume	4
Issue number	2
DOIs	https://doi.org/10.1097/HS9.0000000000000350
Publication status	Published - 1 Apr 2020

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Swan D;Gurney M;Krawczyk J;Ryan AE;ODwyer M
Swan D;Gurney M;Krawczyk J;Ryan AE;O'Dwyer M;

Access to Document

10.1097/HS9.0000000000000350

Cite this

@article{bccbf5f39b8d477a820ff6bd334d57e3,

title = "Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma",

abstract = "The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.",

author = "Dawn Swan and Mark Gurney and Janusz Krawczyk and Ryan, \{Aideen E.\} and Michael O'Dwyer",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 the Author(s).",

year = "2020",

month = apr,

day = "1",

doi = "10.1097/HS9.0000000000000350",

language = "English",

volume = "4",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley and Sons Inc",

number = "2",

}

TY - JOUR

T1 - Beyond DNA damage

T2 - Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma

AU - Swan, Dawn

AU - Gurney, Mark

AU - Krawczyk, Janusz

AU - Ryan, Aideen E.

AU - O'Dwyer, Michael

PY - 2020/4/1

Y1 - 2020/4/1

N2 - The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.

AB - The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.

UR - https://www.scopus.com/pages/publications/85099906024

U2 - 10.1097/HS9.0000000000000350

DO - 10.1097/HS9.0000000000000350

M3 - Review article

SN - 2572-9241

VL - 4

JO - HemaSphere

JF - HemaSphere

IS - 2

M1 - e350

ER -

Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma

Abstract

Authors (Note for portal: view the doc link for the full list of authors)

Access to Document

Other files and links

Fingerprint

Cite this